Benzimidazole-core as an antimycobacterial agent.

作者: Rangappa S. Keri , Chethana Kolambae Rajappa , Siddappa A. Patil , Bhari Mallanna Nagaraja

DOI: 10.1016/J.PHAREP.2016.08.002

关键词:

摘要: Mycobacterium tuberculosis (Mtb) is considered as one of the precarious bacterial infections around world. Through a projected 8.7 million new (TB) cases and 1.4 mortalities per annum, this deadly infection resulted insubstantial amount human deaths than any other single organism infections. TB India’s most threatening health problems it accounts for approximately 33% global issues. Subsequently, there an imperative need improvement existing drug candidates with newer targets specified mechanism action. Within wide spectra heterocycles, benzimidazole its substituted analogues were evidenced promising biological efficacies enabling them to perform or prodrug candidates. Exceptional structural features class heterocycle versatile applications made privileged backbone in design discovery. Majorly, 2,5- 2,6-disubstituted derivatives shown induce significant antiTB potential. To seek more insights on unique feature candidates, urgency assemble recent advances area. This review presents overview advancements focuses responsible compiled published reports emphasizing different approaches employed their syntheses order help medicinal clinical chemists designing next generation, yet effective safer

参考文章(81)
Kazuo Kobayashi, Masaji Okada, Recent progress in mycobacteriology Kekkaku(Tuberculosis). ,vol. 82, pp. 783- 799 ,(2007)
M. C. Becerra, J. Bayona, J. Y. Kim, P. E. Farmer, J. Freeman, Redefining MDR-TB transmission 'hot spots' International Journal of Tuberculosis and Lung Disease. ,vol. 4, pp. 387- 394 ,(2000)
Geeta Yadav, Swastika Ganguly, Structure activity relationship (SAR) study of benzimidazole scaffold for different biological activities: A mini-review European Journal of Medicinal Chemistry. ,vol. 97, pp. 419- 443 ,(2015) , 10.1016/J.EJMECH.2014.11.053
Lynn G. Dover, Geoffrey D. Coxon, Current status and research strategies in tuberculosis drug development. Journal of Medicinal Chemistry. ,vol. 54, pp. 6157- 6165 ,(2011) , 10.1021/JM200305Q
Beena, Diwan S. Rawat, Antituberculosis drug research: a critical overview. Medicinal Research Reviews. ,vol. 33, pp. 693- 764 ,(2013) , 10.1002/MED.21262
F. Hobrecker, Ueber Reductionsprodukte der Nitracetamidverbindungen European Journal of Inorganic Chemistry. ,vol. 5, pp. 920- 924 ,(1872) , 10.1002/CBER.18720050295
Claire Harper, Tuberculosis, a neglected opportunity? Nature Medicine. ,vol. 13, pp. 309- 312 ,(2007) , 10.1038/NM0307-309
Francis E. Umesiri, Aditya K. Sanki, Julie Boucau, Donald R. Ronning, Steven J. Sucheck, Recent advances toward the inhibition of mAG and LAM synthesis in Mycobacterium tuberculosis. Medicinal Research Reviews. ,vol. 30, pp. 290- 326 ,(2010) , 10.1002/MED.20190
P Karuvalam Ranjith, P Rajeesh, Karickal R Haridas, Nayak K Susanta, Tayur N Guru Row, R Rishikesan, N Suchetha Kumari, None, Design and synthesis of positional isomers of 5 and 6-bromo-1-[(phenyl)sulfonyl]-2-[(4-nitrophenoxy)methyl]-1H-benzimidazoles as possible antimicrobial and antitubercular agents Bioorganic & Medicinal Chemistry Letters. ,vol. 23, pp. 5228- 5234 ,(2013) , 10.1016/J.BMCL.2013.06.072